TY - JOUR
T1 - Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells
AU - Morales, Johanna K.
AU - Kmieciak, MacIej
AU - Graham, Laura
AU - Feldmesser, Marta
AU - Bear, Harry D.
AU - Manjili, Masoud H.
N1 - Funding Information:
Acknowledgments This work was supported by NIH R01 CA104757 grant (M. H. Manjili) and Xow cytometry shared resources facility supported in part by the NIH grant P30CA16059. We thank Daniel Conrad and Jamie Sturgill for their assistance with puriWcation of the anti-Gr1 antibody. We gratefully acknowledge the support of VCU Massey Cancer Centre and the Commonwealth Foundation for Cancer Research, Department of Defense Grant BC083048.
PY - 2009/6
Y1 - 2009/6
N2 - Adoptive immunotherapy (AIT) using ex vivo-expanded HER-2/neu-specific T cells has shown initial promising results against disseminated tumor cells in the bone marrow. However, it has failed to promote objective responses against primary tumors. We report for the first time that alternating gamma chain cytokines (IL-2, IL-7 and IL-15) ex vivo can expand the neu-specific lymphocytes that can kill breast tumors in vitro. However, the anti-tumor efficacy of these neu-specific T cells was compromised by the increased levels of myeloid-derived suppressor cells (MDSC) during the premalignant stage in FVBN202 transgenic mouse model of breast carcinoma. Combination of AIT with the depletion of MDSC, in vivo, resulted in the regression of neu positive primary tumors. Importantly, neu-specific antibody responses were restored only when AIT was combined with the depletion of MDSC. In vitro studies determined that MDSC caused inhibition of T cell proliferation in a contact-dependent manner. Together, these results suggest that combination of AIT with depletion or inhibition of MDSC could lead to the regression of mammary tumors.
AB - Adoptive immunotherapy (AIT) using ex vivo-expanded HER-2/neu-specific T cells has shown initial promising results against disseminated tumor cells in the bone marrow. However, it has failed to promote objective responses against primary tumors. We report for the first time that alternating gamma chain cytokines (IL-2, IL-7 and IL-15) ex vivo can expand the neu-specific lymphocytes that can kill breast tumors in vitro. However, the anti-tumor efficacy of these neu-specific T cells was compromised by the increased levels of myeloid-derived suppressor cells (MDSC) during the premalignant stage in FVBN202 transgenic mouse model of breast carcinoma. Combination of AIT with the depletion of MDSC, in vivo, resulted in the regression of neu positive primary tumors. Importantly, neu-specific antibody responses were restored only when AIT was combined with the depletion of MDSC. In vitro studies determined that MDSC caused inhibition of T cell proliferation in a contact-dependent manner. Together, these results suggest that combination of AIT with depletion or inhibition of MDSC could lead to the regression of mammary tumors.
KW - Adoptive immunotherapy
KW - Breast cancer
KW - Gamma chain cytokines
KW - HER-2/neu
KW - Myeloid-derived suppressor cells
UR - http://www.scopus.com/inward/record.url?scp=63949088142&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=63949088142&partnerID=8YFLogxK
U2 - 10.1007/s00262-008-0609-z
DO - 10.1007/s00262-008-0609-z
M3 - Article
C2 - 18979098
AN - SCOPUS:63949088142
SN - 0340-7004
VL - 58
SP - 941
EP - 953
JO - Cancer Immunology, Immunotherapy
JF - Cancer Immunology, Immunotherapy
IS - 6
ER -